Skip to main content
Erschienen in: Reactions Weekly 1/2020

01.08.2020 | Clinical study

Ipilimumab increases risk of bowel injury

Erschienen in: Reactions Weekly | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Excerpt

While ipilimumab appears to increase the risk of bowel injury, there are insufficient data to distinguish between the risk of chronic enterocolitis (lasting ≥6 weeks) versus acute enterocolitis (lasting <6 weeks), or between the risk of enterocolitis, enteritis and colitis, say authors of a systematic review and meta-analyses published in Drug Safety. …
Metadaten
Titel
Ipilimumab increases risk of bowel injury
Publikationsdatum
01.08.2020
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2020
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-020-81967-7

Weitere Artikel der Ausgabe 1/2020

Reactions Weekly 1/2020 Zur Ausgabe

Case report

Imatinib

Case report

Bortezomib

Case report

Pembrolizumab